BRAF and melanoma: Finally, in a phase III trial of nivolumab in previously untreated advanced melanoma patients (without BRAF mutations), ICB therapy was demonstrated to have significantly higher efficacy compared with dacarbazine with a 1 year survival rate of 72.9% in the nivolumab treated group versus 42% in the dacarbazine group (189).